Retinoblastoma Treatment Market Report, Global, 2024

The retinoblastoma treatment market size has grown strongly in recent years. It will grow from $1.93 billion in 2023 to $2.03 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The historical growth can be attributed to an increasing number of funding sources, the likelihood of retinoblastoma recurrence, early diagnosis and treatment of retinoblastoma, growing awareness regarding different types of cancers, and significant advancements in cancer research.

The retinoblastoma treatment market size is expected to see strong growth in the next few years. It will grow to $2.56 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The anticipated growth in the forecast period can be attributed to the rising demand for ophthalmic treatment and surgeries, the increasing incidence of retinoblastoma, expanding research and development activities, growing awareness regarding retinoblastoma treatment, and escalating healthcare expenditure. Significant trends expected in the forecast period encompass advancements in medical technology, enhanced diagnostic capabilities, increased investments in pediatric oncology, approvals of new products, and enhancements in medical infrastructure.

The rising need for ophthalmic treatment and surgeries is anticipated to drive the expansion of the retinoblastoma treatment market in the foreseeable future. Ophthalmic treatment and surgeries encompass a range of medical interventions and procedures aimed at diagnosing, managing, and correcting disorders affecting the eyes and visual system. This demand surge is attributed to factors such as an aging population, increased prevalence of conditions such as cataracts and age-related macular degeneration, technological advancements enabling more efficient and accessible treatments, and heightened awareness leading to earlier detection and intervention. Retinoblastoma treatment is essential for ophthalmic surgeries aimed at addressing cancerous growths within the eye(s), preventing metastasis or recurrence, while also preserving vision and eye function. For example, in September 2023, a report from the UK's Office for Health Improvement and Disparities revealed over 4.09 million admissions for cataract surgery in England, with a rate of 3,803 (3,789 to 3,816) per 100,000 population in the financial year ending 2022. Additionally, there were over 10,900 admissions for rhegmatogenous retinal detachment surgeries and over 677,000 intravitreal injection therapy procedures performed during the same period, with rates of 23.4 (22.9 to 24.0) and 4,796 (4,769 to 4,823) per 100,000 population, respectively. Consequently, the rising demand for ophthalmic treatment and surgeries is propelling the growth of the retinoblastoma treatment market.

Key players in the retinoblastoma treatment market are dedicated to developing innovative solutions, such as oncolytic adenovirus, to cater to the evolving needs of customers with enhanced functionalities. An oncolytic adenovirus is a genetically modified virus designed to infect and selectively destroy cancer cells while sparing normal cells. For instance, in February 2022, VCN Biosciences, a biotechnology company based in Spain, received orphan drug designation from the U.S. Food and Drug Administration for VCN-01, a genetically engineered oncolytic adenovirus intended for retinoblastoma treatment. VCN-01's distinctive feature lies in its oncolytic adenovirus nature, which is currently undergoing clinical trials targeting cancers with no definitive cure, including pancreatic carcinoma and retinoblastoma (RB). VCN-01 has undergone scrutiny in four phase 1 clinical trials and is being investigated as a standalone treatment option for RB patients who have previously undergone unsuccessful chemotherapy. Intravitreal administration of VCN-01 has demonstrated complete remission and tumor reduction in several patients, paving the way for its orphan drug status approval.

In March 2022, Synthetic Biologics Inc., a biotechnology company based in the United States, acquired VCN Biosciences S.L. for an undisclosed sum. This acquisition represents a significant advancement in Synthetic Biologics' pipeline, integrating VCN's primary clinical-stage drug candidate, VCN-01. VCN Biosciences S.L. is a biotechnology company based in Spain specializing in retinoblastoma treatment.

Major companies operating in the retinoblastoma treatment market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Otsuka Pharmaceutical, Daiichi Sankyo Company, Taiho Pharmaceutical Co. Ltd., Icon Bioscience Inc., Ono Pharmaceutical Co. Ltd., Nippon Shinyaku Co. Ltd., Cadila Pharmaceuticals, Arcus Biosciences Inc., Sheba Medical Center, Cellceutix Corporation, Phio Pharmaceuticals Inc.

North America was the largest region in the retinoblastoma treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinoblastoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the retinoblastoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Retinoblastoma treatment encompasses medical interventions and therapies directed at diagnosing, managing, and potentially curing retinoblastoma, a rare type of eye cancer predominantly found in young children, typically before the age of five. The primary objective of retinoblastoma treatment is to eliminate or control the cancerous growths within the eye(s) while preserving vision and minimizing the risk of metastasis or recurrence.

The main types of retinoblastoma treatment include non-hereditary retinoblastoma and hereditary retinoblastoma. Non-hereditary retinoblastoma, a rare cancer affecting children under six years old, encompasses various treatment modalities such as surgery, radiation therapy, laser therapy (photocoagulation), cryotherapy, thermotherapy, chemotherapy, ophthalmic artery infusion chemotherapy, and high-dose chemotherapy with stem cell transplant. These treatments are applicable to both intraocular and extraocular retinoblastoma stages and are commonly administered in hospitals, cancer institutes, and other medical facilities.

The retinoblastoma treatment market research report is one of a series of new reports that provides retinoblastoma treatment market statistics, including retinoblastoma treatment industry global market size, regional shares, competitors with a retinoblastoma treatment market share, detailed retinoblastoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the retinoblastoma treatment industry. This retinoblastoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The retinoblastoma treatment market consists of revenues earned by entities by providing services such as multidisciplinary care, genetic testing and counseling, remote patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinoblastoma treatment market also includes sales of targeted therapy medications, genetic testing kits and intravitreal chemotherapy injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.